Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mononuclear cells + umbilical cord mesenchymal stromal cells
- Development stage
- Unknown
- Lead developer
- Cellonis Biotechnologies
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intra-arterial, Intramuscular, Intrathecal
01
Overview
Autologous bone marrow mononuclear cells + umbilical cord mesenchymal stromal cells is a combination cell therapy investigated for the treatment of type 1 diabetes (T1D), type 2 diabetes (T2DM), and osteonecrosis. The therapy involves the co-transplantation of allogeneic mesenchymal stromal cells (MSCs) derived from umbilical cord tissue and autologous mononuclear cells (MNCs) derived from the patient's own bone marrow. This regenerative medicine approach aims to restore pancreatic beta-cell function, improve insulin secretion, and reduce chronic diabetic complications through immunomodulation and potential tissue regeneration. Clinical administration typically involves supraselective pancreatic artery cannulation for diabetes or femoral artery infusion for osteonecrosis.
- Other names
- UC-MSC + aBM-MNCco-transplantation of umbilical cord MSCs and aBM-MNCsautologous bone marrow-derived mononuclear cell + human umbilical cord mesenchymal stem cells
Beyond the preview
Go deeper on autologous bone marrow mononuclear cells + umbilical cord mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mononuclear cells + umbilical cord mesenchymal stromal cells.